SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2482From EU label extension: centerforbiosimilars.com <Said Michael Devoy, MD, Miljenko Zuanic-8/19/2018
2481CMS changes that involve iv-avastin is much bigger treat than competitions. And Miljenko Zuanic-8/19/2018
2480I am not as worried about the threat to Eylea, similar to Humira they will have Felix B-8/18/2018
2479REGN agree on weaker claim on efficacy, and option for 12/16 weeks interval onlyMiljenko Zuanic-8/18/2018
2478Curious what was changed in a few days...Felix B-8/17/2018
2477As predicted, 12w Eylea dosing regime approved. The SHORTEST CRL in FDA history,Miljenko Zuanic-8/17/2018
2476It was not pre-specified analysis (it was per protocol, from start, second year,Miljenko Zuanic-8/15/2018
2475I thought this would be a sure thing...and now with medicare news I am not sure Felix B-8/15/2018
2474REGN marker reaction on CRL from FDA: Stupid Mr. Market can not think strait! TMiljenko Zuanic-8/13/2018
2473Eylea 12w interval regimen temporary (and maybe permanently) rejected by FDA. PrMiljenko Zuanic-8/13/2018
2472REGN 2Q pps gains did not last long....long feared Eylea price control by CMC paMiljenko Zuanic-8/8/2018
2471Finally, they recognized urgency for speed: files.shareholder.com Two horses caMiljenko Zuanic-8/6/2018
2470China Eylea version: asrs.orgMiljenko Zuanic-8/2/2018
24692Q: files.shareholder.com Eylea US sale (992M) was bit light from my assumptionMiljenko Zuanic-8/2/2018
2468CELG is silent about A317, analysts have no clue!Miljenko Zuanic-7/26/2018
2467Also, bear in mind subjects (in Roche trial) were those who initially responded Miljenko Zuanic-7/26/2018
2466Thanks. I question the desirability for patients of getting an implant that needDewDiligence_on_SI-7/26/2018
2465<What exactly do you mean by, "no clear cut"?> What fixed dose Miljenko Zuanic-7/26/2018
2464What exactly do you mean by, "no clear cut"?DewDiligence_on_SI-7/26/2018
2463No clear cut for Roche L-implant PDS in AMD: roche.com and roche.com Also, US LMiljenko Zuanic17/26/2018
2462RE: BGNE (A317) 2L NSCLC : clinicaltrials.gov After 8 months, only single centeMiljenko Zuanic-7/24/2018
2461Off (on ) Topic: BGNE, RE: BGB-A317 (anti-PD1) PS 1L ns NSSLC (320 subjects) v Miljenko Zuanic-7/24/2018
2460Not a serious Eylea competitor (Abicipar, inflammation is a killer, efficacy notMiljenko Zuanic-7/19/2018
2459Still, no clear path to finish line (from Pfizer anti-NGFprogram): fiercebiotechMiljenko Zuanic-7/18/2018
2458Earnings in a few more weeks - hopefully big push from that.Felix B-7/13/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News
===========================================================================================================================